The incentive programs for senior management and key individuals implemented during 2013 and 2014 entitles, through the exercise of options, the holders to subscribe for new shares in the company during the second half of 2017. In total, the incentive programs consist of 159,000 options which entitle the holders to one new share per option.
During the month of December, a total of 11,000 shares have been issued through the exercise of the incentive programs’ options. There are 6,000 unexercised options at the conclusion of the programs.
As of December 31, 2017, there are a total of 4,854,138 shares and votes in the company.
At year-end, there would have been a total of 4,860,138 shares and votes in the company if the incentive programs’ options had been fully exercised.
For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46 705-58 51 05
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 705-46 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a rapidly growing global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden and the USA. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
This information is information that Boule Diagnostics AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). This information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET December 29, 2017.